May 20 |
Ensysce Biosciences Continues Collaboration to Advance the Clinical Development of Innovative Overdose Protection Platform
|
May 14 |
Ensysce Biosciences First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
May 13 |
Ensysce Biosciences GAAP EPS of -$0.55
|
May 13 |
Ensysce Biosciences Reports First Quarter 2024 Financial Results
|
May 13 |
ENSC: Quarterly Report Highlights Progress
|
Apr 25 |
Ensysce Biosciences’ CEO Dr. Lynn Kirkpatrick Featured in Xtalks Clinical Edge Magazine
|
Apr 19 |
Ensysce Biosciences' Presentation from the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference Published
|
Apr 9 |
Ensysce Biosciences to Participate in the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
|